Bilen et al. perform a phase 2 single-arm clinical trial of neoadjuvant cabozantinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma, assess efficacy and find antitumor CD8+ T cell response activation upon treatment.
- Mehmet A. Bilen
- BaoHan T. Vo
- Viraj A. Master